Abstract
▴ Exenatide is an incretin mimetic. It improves glycaemic control via various glucoregulatory mechanisms, including glucose-dependent insulinotropism, suppression of inappropriately high glucagon levels, delayed gastric emptying and reduction of food intake.
▴ In three large, well designed, phase III trials in adults with type 2 diabetes mellitus and suboptimal glycaemic control despite treatment with metformin and/or a sulfonylurea, mean changes from baseline in glycosylated haemoglobin (HbA1c) significantly favoured subcutaneous exenatide 5 or 10μg twice daily over placebo after 30 weeks’ treatment (primary endpoint).
▴ Relative to placebo, reductions from baseline in bodyweight were significantly greater with twice-daily exenatide 5 μg (in two studies) or 10μg (in all three studies).
▴ Post hoc completer analyses revealed that the beneficial effects of exenatide on HbA1c and body-weight were maintained for up to 82 weeks.
▴ Adjunctive therapy with subcutaneous exenatide 10μg twice daily improved glycaemic control to a similar extent as insulin glargine in patients with type 2 diabetes suboptimally controlled with metformin plus a sulfonylurea in a large, well designed, 26-week, phase III trial.
▴ Subcutaneous exenatide was generally well tolerated in patients with type 2 diabetes. The incidence of hypoglycaemia in patients receiving exenatide plus metformin was similar to that seen in placebo plus metformin recipients; however, in patients receiving a sulfonylurea (with or without metformin), the incidence of hypoglycaemia was numerically higher with exenatide than with placebo.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837–53
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005 Jan; 28 Suppl. 1: S4–S36
American College of Endrocrinology. American College of Endrocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002 Jan/Feb; 8 Suppl. 1: 5–11
Clemens A, Siegel E, Gallwitz B. Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids — update on the background of the current guidelines. Exp Clin Endocrinol Diabetes 2004 Oct; 112(9): 493–503
Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metab Disord 2002; 2: 63–82
UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995 Nov; 44: 1249–58
Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77–88
Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002 Mar; 87(3): 1282–90
Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004 Sep; 53(9): 2397–403
Blase E, Taylor K, Gao H-Y, et al. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005 May; 45(5): 570–7
Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001 Jul; 281 (1): E155-61
Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003 Jul; 88(7): 3082–9
Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005 Jan 15; 62(2): 173–81
Linnebjerg H, Kothare P, Skrivanek Z, et al. Exenatide: postprandial glucose pharmacodynamics at various dosing times relative to a meal in patients with type 2 diabetes [abstract no. 776]. Diabetologia 2004 Aug; 47 Suppl. 1: A280. Plus poster presented at the 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5–9; Munich
Fehse F, Trautmann ME, Holst JJ, et al. Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [abstract no. 772]. Diabetologia 2004 Aug; 47 Suppl. 1: A279
Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003 Jun; 284(6): E1072–9
Mari A, Halseth A, Nanayakkara N, et al. Mathematical modeling shows exenatide improved postprandial β-cell function in patients with type 2 diabetes treated with metformin or metformin and sulfonylurea [abstract no. 482-P]. Diabetes 2005; 54 Suppl. 1: A119. Plus poster presented at the 65th Annual Scientific Sessions of the American Diabetes Association; 2005 Jun 10–14; San Diego (CA)
Hiles R, Carpenter T, Serota D, et al. Exenatide does not cause pancreatic islet cell proliferative lesions in rats and mice following 2-year exposure [abstract no. 1585-P]. Diabetes 2004 Jun; 53 Suppl. 2: A380
Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob,db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999 May; 48: 1026–34
Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001 May; 50(5): 583–9
Joy SV, Rodgers PT, Scates AC. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005 Jan; 39(1): 110–8
Amylin Pharmaceuticals, Inc. Byetta™ (exenatide injection): prescribing information [online]. Available from URL: http:// www.byetta.com [Accessed 2005 May 9]
Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003 Aug; 26(8): 2370–7
Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005 Apr; 146(4): 2069–76
Soon D, Linnebjerg H, Chan C, et al. Effect of exenatide on digoxin pharmacokinetics [abstract no. PO-047]. Clin Exp Pharmacol Physiol 2004 Aug; 31 Suppl. 1: A65
Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005 Feb; 27(2): 210–5
Kothare P, Linnebjerg H, Atkins M, et al. Effect of exenatide on lisinopril pharmacodynamcis in patients treated for hypertension [abstract no. PI-24]. Clin Pharmacol Ther 2005 Feb; 77(2): P14
Linnebjerg H, Kothare P, Park S, et al. Exenatide pharmacokinetics in patients with mild to moderate renal dysfunction and end stage renal disease [abstract no. 469-P]. Diabetes 2005; 54 Suppl. 1: A116
Hiles RA, Bawdon RE, Petrella EM. Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Hum Exp Toxicol 2003 Dec; 22(12): 623–8
Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005 Jun; 7(3): 467–77
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 May; 28(5): 1092–100
Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 Nov; 27(11): 2628–35
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 May; 28(5): 1083–91
Kim D, Trautmann ME, Herrmann K, et al. Exenatide reduzierte HbA1c und gewicht über 82 wochen bei patienten mit typ-2 diabetes in kombination mit metformin [abstract no. V-20]. Diabetes Stoffwechsel 2005; 14 Suppl. 1: 10
Kim D, Trautmann ME, Limmer J, et al. Exenatide reduzierte HbA1c und gewicht über 82 wochen bei mit sulfonylharnstoff behandelten patienten mit typ-2 diabetes [abstract no. P-351]. Diabetes Stoffwechsel 2005; 14 Suppl. 1: 162
Kim D, Trautmann ME, Schönamsgruber E, et al. Exenatide reduzierte HbA1c und gewicht über 82 wochen bei mit metformin und sulfonylharnstoff behandelten patienten mit typ-2 diabetes [abstract no. P-349]. Diabetes Stoffwechsel 2005; 14 Suppl. 1: 161
Kendall DM, Kim D, Poon T, et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 wk [abstract no. 16-OR]. Diabetes 2005; 54 Suppl. 1: A4–5
Heine RJ, Van Gaal LF, Johns D, et al. Comparison of exenatide and insulin glargine in MET- and SU-treated patients with type 2 diabetes: exenatide achieved equivalent glycemic control, with weight reduction and less nocturnal hypoglycemia [abstract no. 9-OR]. Diabetes 2005; 54 Suppl. 1: A3. Plus oral presentation at the 65th Annual Scientific Sessions of the American Diabetes Association; 2005 Jun 10–14; San Diego (CA)
Maggs D, Kim D, Holcombe J, et al. Exenatide-induced reductions in A1C and body weight in long-term trials are not explained by gastrointestinal side effects [abstract no. 485-P]. Diabetes 2005; 54 Suppl. 1: A120. Plus poster presented at the 65th Annual Scientific Sessions of the American Diabetes Association; 2005 Jun 10–14; San Diego (CA)
Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004 Sep–Oct; 20(5): 411–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keating, G.M. Exenatide. Drugs 65, 1681–1692 (2005). https://doi.org/10.2165/00003495-200565120-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565120-00008